Tandem Diabetes reports Q3 EPS (31c), consensus (34c)

Reports Q3 revenue $249.3M, consensus $235.8M. “Tandem delivered a strong third quarter performance marked by record quarterly sales, significant gross margin improvement, and meaningful progress on our key strategic initiatives,” said John Sheridan, president and chief executive officer. “We are beginning to see the positive impact of our business transformation, which strengthens our ability to achieve Tandem’s near- and longer-term goals, while continuing our commitment to improve the lives of people with diabetes.”